BW A515U（6-脱氧阿昔洛韦）用于慢性乙型肝炎病毒感染的一项初步研究。
A pilot study of BW A515U (6-deoxyacyclovir) in chronic hepatitis B virus infection.
作者信息
Weller I V, Tedder R S, Karayiannis P, Thomas H C, Fiddian A P
出版信息
J Hepatol. 1986;3 Suppl 2:S119-22. doi: 10.1016/s0168-8278(86)80109-x.
PMID:3598153
Abstract
BW A515U (6-Deoxyacyclovir) is a pro-drug of acyclovir and almost 100% is absorbed orally. 250 mg orally 6-hourly for 10 days was given to 4 hepatitis B surface antigen/e antigen-positive carriers. No consistent effect on productive viral replication, as determined by serum DNA polymerase and DNA levels was observed. The changes that occurred in these markers and transaminases in 1 patient were attributed to a spontaneous depression of productive viral replication.
摘要
BW A515U（6-脱氧阿昔洛韦）是阿昔洛韦的前体药物，口服吸收率几乎达100%。对4名乙肝表面抗原/ e抗原阳性携带者每6小时口服250毫克，持续10天。未观察到对由血清DNA聚合酶和DNA水平所确定的病毒复制产生持续影响。1名患者中这些标志物和转氨酶发生的变化归因于病毒复制的自发性抑制。
Zotero 插件